's Unit-V of Apitoria Pharma has been classified as VAI by the USFDA following an inspection conducted from December 1-12, 2025. The inspection resulted in Form 483 being issued with three observations. The VAI classification indicates objectionable conditions that require correction but do not warrant severe regulatory action, allowing continued operations while the company addresses the identified concerns. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.